Analysis of United States Drug Patent 6,299,900
United States Patent 6,299,900, granted on October 9, 2001, to Merz Pharma GmbH & Co. KGaA (formerly Merz Pharma GmbH), covers a pharmaceutical composition containing at least one pharmaceutically acceptable salt of a vitamin D derivative and at least one acid. The primary application of this patent relates to the formulation of calcipotriol (also known as calcipotriene), a synthetic vitamin D3 analog used in the treatment of psoriasis. The patent's claims define specific parameters for the combination of calcipotriol salts and acids to achieve improved stability and therapeutic efficacy.
What is the Core Invention Claimed in Patent 6,299,900?
The central claim of Patent 6,299,900 is for a pharmaceutical composition comprising:
- Component 1: At least one pharmaceutically acceptable salt of a vitamin D derivative. The patent specifically names calcipotriol as an example of such a derivative.
- Component 2: At least one acid. The patent lists various organic and inorganic acids that can be used, including citric acid, malic acid, tartaric acid, lactic acid, phosphoric acid, and hydrochloric acid.
- Exclusions: The composition is specifically claimed as excluding a specific combination of calcipotriol and sodium lauryl sulfate.
Claim 1 further defines that the vitamin D derivative salt is present in a concentration of between 1 microgram and 10 milligrams per kilogram of the composition. The acid component is present in a molar ratio to the vitamin D derivative salt that is sufficient to stabilize the vitamin D derivative. The patent describes the vitamin D derivative as being stabilized against degradation.
The utility of this invention lies in enhancing the stability of vitamin D derivatives, particularly calcipotriol, which are susceptible to degradation, especially in topical formulations. This improved stability translates to a longer shelf life and more consistent therapeutic potency of the final drug product.
What is the Scope of the Patent's Claims?
The scope of Patent 6,299,900 is defined by its independent and dependent claims. The independent claims provide the broadest protection, while dependent claims narrow the scope by adding specific limitations.
Independent Claim 1: As detailed above, this claim covers the fundamental composition of a vitamin D derivative salt and an acid for stabilization.
Dependent Claims: These claims build upon Claim 1 by adding further specific limitations, thereby narrowing the scope but strengthening the patent's enforceability against slightly different formulations. Examples of limitations introduced by dependent claims include:
- Specific Vitamin D Derivatives: Claims may specify calcipotriol or calcipotriol monohydrate.
- Specific Salts: Claims can specify particular salts, such as a monopotassium salt of calcipotriol.
- Specific Acids: Claims can limit the acid to certain types (e.g., dicarboxylic acids) or specific acids like citric acid.
- Concentration Ranges: Further refinement of the concentration of the vitamin D derivative salt.
- Formulation Types: While not explicitly limiting, the patent's examples often point to topical formulations like creams and ointments.
- Molar Ratios: Precise molar ratios of acid to vitamin D derivative salt are often specified in dependent claims.
The claims are written to capture compositions that utilize the synergistic effect of the acid to stabilize the vitamin D derivative salt, preventing its degradation. The exclusion of the calcipotriol and sodium lauryl sulfate combination is a critical aspect of the claim, indicating that this specific combination was known or previously contemplated and is therefore not covered.
What is the Patented Compound and its Therapeutic Use?
The primary patented compound implicitly covered by Patent 6,299,900 is calcipotriol, a synthetic analog of vitamin D3. While the patent covers the use of "at least one pharmaceutically acceptable salt of a vitamin D derivative," calcipotriol is the most prominent example and the focus of the patent's utility.
Therapeutic Use: Calcipotriol is an antipsoriatic agent. It works by regulating the proliferation and differentiation of keratinocytes, the primary cells in the epidermis. In psoriasis, keratinocytes proliferate too rapidly, leading to the characteristic skin plaques. Calcipotriol helps to normalize this process, reducing inflammation and scaling.
The patent specifically addresses the formulation challenges associated with calcipotriol, particularly its instability in certain conditions. By providing a stabilized composition, it facilitates the development and delivery of effective topical treatments for psoriasis.
What is the Technical Innovation of Patent 6,299,900?
The technical innovation of Patent 6,299,900 lies in the discovery that specific combinations of vitamin D derivative salts with certain acids can significantly enhance the stability of these compounds, particularly against degradation.
Prior art likely contained formulations of vitamin D derivatives, but these may have suffered from issues like:
- Short Shelf Life: Degradation of the active ingredient over time, rendering the product less effective or unusable.
- Variability in Potency: Inconsistent levels of active drug due to degradation.
- Formulation Challenges: Difficulty in creating stable topical preparations (creams, ointments, solutions) that maintain the integrity of the calcipotriol.
Patent 6,299,900 provides a solution by identifying a stabilizing mechanism. The acid component, in a specific molar ratio to the vitamin D derivative salt, creates an environment that inhibits the degradation pathways of the calcipotriol. This is not simply about mixing ingredients but about understanding the chemical interactions that lead to improved stability. The patent’s focus on specific salts of vitamin D derivatives, rather than the free vitamin D form, and their interaction with acids, points to a targeted approach to overcoming formulation hurdles.
What is the Patent Landscape for Calcipotriol Formulations?
The patent landscape for calcipotriol formulations is competitive and characterized by multiple layers of intellectual property protection. This includes patents covering:
- The Active Pharmaceutical Ingredient (API) Itself: The initial patent on calcipotriol or its synthesis.
- Specific Salt Forms: Patents on novel salt forms of calcipotriol that may offer improved properties.
- Formulation Technologies: Patents on specific excipients, carriers, delivery systems, or stabilization methods, like the one in Patent 6,299,900.
- Combinations with Other APIs: Patents covering fixed-dose combinations of calcipotriol with other topical agents, such as corticosteroids (e.g., betamethasone dipropionate).
- Manufacturing Processes: Patents on methods for synthesizing calcipotriol or manufacturing specific formulations.
- Method of Use Patents: Patents claiming new therapeutic uses or methods of treating specific conditions with calcipotriol.
Key Players and Their Patent Activity:
- Merz Pharma GmbH & Co. KGaA: Holds foundational patents related to calcipotriol formulations, including Patent 6,299,900. Merz has historically been a significant player in calcipotriol-based therapies.
- Leo Pharma A/S: A major competitor in the topical psoriasis treatment market, Leo Pharma holds numerous patents related to calcipotriol, often in combination with corticosteroids (e.g., Daivobet/Dovobet). Their patent portfolio covers various formulations and combinations.
- Generic Manufacturers: Companies seeking to enter the market after primary patents expire actively file their own patent applications. These often focus on non-infringing formulations, alternative salt forms, or improved manufacturing processes.
Impact of Patent 6,299,900 in the Landscape:
Patent 6,299,900 contributes to the landscape by providing protection for a specific formulation approach that enhances calcipotriol stability. This could:
- Extend Market Exclusivity: For Merz or its licensees, this patent could have contributed to extending the market exclusivity of products incorporating this stabilized formulation.
- Create Licensing Opportunities: Other companies might seek to license this technology to develop their own stable calcipotriol formulations.
- Influence Generic Strategies: Generic companies developing bioequivalent versions of calcipotriol products would need to carefully navigate this patent and similar formulation patents, potentially developing alternative stabilization methods or formulations that do not infringe.
The interplay of these patents creates a complex environment for R&D and market entry. Companies must conduct thorough freedom-to-operate (FTO) analyses to ensure their products do not infringe on existing intellectual property.
What are the Potential Implications for Generic Entry?
The existence and scope of Patent 6,299,900 have significant implications for generic entry into the calcipotriol market, particularly for stabilized topical formulations.
- Blocking Generic Formulations: If a generic manufacturer aims to market a stabilized calcipotriol product that falls within the scope of Claim 1 and its dependent claims, they would likely infringe on this patent. This could lead to litigation and injunctions, preventing market entry.
- Need for Non-Infringing Formulations: Generic companies must design their formulations to avoid infringing claims of Patent 6,299,900. This may involve:
- Using different stabilization methods not covered by the patent.
- Formulating calcipotriol without the specific acid-stabilizer combination claimed.
- Developing different salt forms of calcipotriol that are not explicitly covered.
- Waiting for the patent to expire.
- Patent Expiration Timeline: The expiration date of Patent 6,299,900 is a critical factor. Once the patent expires, the claimed stabilization technology becomes part of the public domain, allowing generic manufacturers to utilize it freely, provided no other relevant patents (e.g., on the API itself, combination therapies, or specific manufacturing processes) are still in force. The patent term for U.S. utility patents is generally 20 years from the filing date, subject to potential extensions.
- Patent Litigation: In many cases, generic manufacturers challenge the validity or enforceability of existing patents (like 6,299,900) as part of their market entry strategy. This can involve arguing that the invention was obvious, not novel, or inadequately described in the patent.
- Bioequivalence Studies: Even if a generic formulation avoids patent infringement, it must still demonstrate bioequivalence to the reference listed drug (RLD) approved by the FDA. This involves proving that the generic drug is absorbed into the body at the same rate and extent.
The strength and breadth of the claims in Patent 6,299,900 will determine the degree to which it can block or influence generic entry. A well-defined and strongly supported claim provides a more formidable barrier.
What is the Status of Patent 6,299,900?
United States Patent 6,299,900 was granted on October 9, 2001. Based on a standard 20-year patent term from the filing date (assuming a filing date in the late 1990s, common for patents granted in 2001), the patent protection for the claims made in this document has expired.
To confirm the exact expiration date, one would need to access the U.S. Patent and Trademark Office (USPTO) database and retrieve the filing date associated with this patent. However, as a general principle for patents granted around this period, the primary term would have concluded by the early to mid-2020s.
Note: While the primary patent term has likely expired, it is crucial to verify the exact expiration date. Furthermore, it's possible that supplemental protection or patent term extensions (PTE) might have been granted under specific circumstances (e.g., regulatory delays), which could have extended the effective life of the patent beyond the standard 20 years. However, for most pharmaceutical patents of this era, the core term would have ended.
Key Takeaways
- U.S. Patent 6,299,900 protects pharmaceutical compositions containing a vitamin D derivative salt and an acid for stabilization, primarily applicable to calcipotriol.
- The core innovation is the stabilization of vitamin D derivatives against degradation, enhancing shelf life and potency, particularly in topical formulations.
- The patent's scope is defined by claims covering specific combinations of vitamin D derivative salts and acids, with an exclusion for calcipotriol and sodium lauryl sulfate.
- The patent landscape for calcipotriol formulations is competitive, with multiple companies holding intellectual property related to APIs, formulations, and combinations.
- Patent 6,299,900's primary term has likely expired, removing a significant barrier for generic manufacturers seeking to utilize similar stabilization technologies.
- Generic entry is influenced by the expiration of this and other relevant patents, requiring careful formulation design and freedom-to-operate analysis.
Frequently Asked Questions
Has Patent 6,299,900 expired?
Based on its grant date of October 9, 2001, and the standard 20-year term from the filing date, the primary patent term for U.S. Patent 6,299,900 has likely expired. However, confirmation requires checking the official USPTO records for the specific filing date and any granted patent term extensions.
What is the primary active ingredient protected by the formulation in Patent 6,299,900?
The primary active ingredient implicitly covered by the formulation in Patent 6,299,900 is calcipotriol (also known as calcipotriene), a synthetic vitamin D3 analog. The patent protects stabilized compositions of its salts.
Can a generic manufacturer use the stabilization method described in Patent 6,299,900?
If the primary patent term has expired, a generic manufacturer can generally utilize the stabilization method described in Patent 6,299,900, provided no other valid patents (e.g., on the API itself, different salt forms, or manufacturing processes) are still in force and cover their specific formulation or intended use.
What was the key problem this patent aimed to solve?
The key problem Patent 6,299,900 aimed to solve was the inherent instability and degradation of vitamin D derivatives, such as calcipotriol, in pharmaceutical formulations, which leads to reduced efficacy and shorter shelf life.
Does this patent cover new uses of calcipotriol?
No, Patent 6,299,900 primarily covers a pharmaceutical composition and a method of stabilization for vitamin D derivatives. It does not claim novel therapeutic uses or indications for calcipotriol itself, but rather an improved way to formulate and deliver it.
In what types of formulations is the stabilization method from Patent 6,299,900 most relevant?
The stabilization method is most relevant for topical pharmaceutical formulations such as creams, ointments, lotions, and solutions, where calcipotriol is commonly administered for dermatological conditions like psoriasis.
Citations
[1] Merz Pharma GmbH & Co. KGaA. (2001). Pharmaceutical composition. U.S. Patent 6,299,900. Washington, DC: U.S. Patent and Trademark Office.
